Press Releases
Cobalis Corp. Launches National Television Commercials For PreHistin® Allergy Defense Formula
IRVINE, Calif., May 10, 2011 /PRNewswire/ -- Cobalis Corp. (CLSC.PK) announced today they have started airing 60-second television commercials for PreHistin® Allergy Defense Formula, on major national cable and satellite networks across the US.
The commercials, featuring leading US allergist Dr. Paul H. Ratner, MD, explain how PreHistin works at the root cause of allergies, giving seasonal and year-round sufferers the first truly new advance in allergies in many years -- a safe and effective, side-effect free, all natural product intended, in the words of Dr. Ratner, to "help restore a normal response to seasonal and year-round allergies, which is no allergic response at all!" The commercials were created to help build the PreHistin brand to consumers and allergy sufferers, and drive traffic to the pharmacy retailers across the US who now carry PreHistin in their allergy section. The commercials are now being placed on national cable networks and satellite cable providers, in a planned $5 million TV advertising campaign reaching a daily audience of over 300 million Americans, such as ION, Reelz, Great American Country, Style, Cooking Channel, ABC Family, BBC, BIO, OWN, E!, Lifetime, Oxygen, Soapnet, Womens' Entertainment, Style and many others. The spots not only present the PreHistin story and explain the real cause of allergies, but prompt viewers that PreHistin is available now at fine pharmacies everywhere, and to "ask your pharmacist for PreHistin today." Marty Marion, Cobalis CEO said, "We are excited to announce the start of our national TV campaign for PreHistin, which was selected as "Best New Product of 2011" out of a field of over a thousand products at the recent ECRM Cough, Cold and Allergy show. We are committed to supporting those retailers and pharmacies who are selling PreHistin, and television is just one of the support channels we are engaging to drive traffic, stimulate brand awareness and increase sales." Cobalis President Chas Radovich said, "We believe that when allergy sufferers learn the PreHistin story they will try PreHistin for its ability to naturally restore a normal non-reactive response to allergens with no side effects or sedation. We thank the retailers who have brought PreHistin into their stores, and who are partnering with us to build PreHistin into a national brand." PreHistin is now on shelves at one of the nation's two largest drugstore chains, as well as many fine regional and local pharmacies, and is expected to be on the shelf at most pharmacy and grocery shelves across the country very quickly.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |



Connect with TheStreet